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Abstract
Crosstalk between tumor cells and the cognate microenvironment plays a crucial role in tumor initiation and progression.
However, only a few genes are known to affect such a crosstalk. This study reveals that WSX1 plays such a role when highly
expressed in tumor cells. The expression of WSX1 in Lewis Lung Carcinoma (LLC) and the melanoma cell line AGS induces
the death of T cells and inhibits the production of the effector cytokine IFNc from NK and T cells, resulting in the promotion
of tumor growth. These pro-tumorigenic properties of WSX1 are independent of IL27. This key observation reveals a new
pathway of tumor-host interaction, which will ultimately lead to better strategies in immune therapy to reverse tumor
tolerance.
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Introduction
Tumor initiation and progression are dependent on both
aberrant gene expression in tumor cells and the communication
between tumor cells and their microenvironment. Accumulating
evidence in the past decade has shown that the complex
relationship between tumors and immune cells is not a one way
street [1,2]. Studies have found that while some immune cells can
destroy transformed cells, other types of immune cells in the tumor
microenvironment can promote escape of tumor cells from the
immune system and the transition from a pro-inflammatory
immune response into a tolerant state [3]. Multiple tumors have
adopted such pathways to downregulate the immune response,
thus facilitating tumor growth and immune evasion of tumor cells.
Many tumor suppressor genes and oncogenes have been
characterized to suppress or promote tumor growth, but fewer
genes in tumors are characterized to interact with immune cells,
suppress immune cell activities, or trigger tumor tolerance. These
few genes, known as suppressing effector immune cells include:
upregulation of program death ligand 1 (PD-L1), indoleamine 2,3-
dioxygenase (IDO), galectin 3, Fas ligand and so forth
[4,5,6,7,8,9]. Revealing other crucial immune suppressor genes
that affect the communication network between tumor and
immune cells will ultimately result in effective anti-cancer
therapies.
The current literature exclusively indicates that the function of
the IL27 receptor, WSX1, is exclusively associated with IL27 and
IL27’s signaling in immune cells. IL27-independent function of
WSX1 and its association with cancer biology is unknown. One
reason is that WSX1 is primarily known to be expressed in
immune cells such as monocytes, dendritic cells, T and B
lymphocytes, NK, and mast cells [10]. Another reason, perhaps,
is that WSX1 needs to pair with gp130 to constitute a functional
signal-transducing receptor for IL27 signaling, and the absence of
either subunit attenuates IL27-mediated signaling [11]. Recently,
we have found that WSX1 is also expressed in multiple types of
tumor cell lines and that WSX1 has an important role not only in
immune cells but also in cancers of epithelial origin via an IL27-
signaling-independent pathway [12]. This discovery is further
supported by a recent report which revealed that WSX1 is
expressed in another type of epithelial tumor such as melanoma
cells [13].
Our previous findings show that many of the human cell lines
have a high level of WSX1 expression when compared to a normal
control cell line, NCM460, suggesting that WSX1 might promote
tumor growth [12]. Using genetically modified tumor cells, we
present evidence that the overexpression of WSX1 in two
independent tumor models, such as aggressive Lewis Lung
Carcinoma (LLC) and melanoma cell line AGS, promotes tumor
growth independent of IL27 signaling. The underlying mechanism
by which WSX1 promotes tumor growth is dependent on the
presence of an immune surveillance system and the pro-
tumorigenic properties of WSX1 are independent of IL27. This
observation is associated with the induction of immune tolerance
via apoptosis of T cells and the reduction of IFNc in the tumor
microenvironment. This discovery reveals a novel mechanism on
how tumor and immune cells communicate to regulate the tumor
microenvironment and ultimately tumor progression.
Results
The paradoxical functions of WSX1 between in-vivo and
in-vitro assays
We have previously shown that WSX1 is highly expressed not
only in immune cells as reported by others, but also in epithelial
tumor cells [10,12]. The expression of WSX1 in tumor cells
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different cell lines, AT84 and TC1. We aimed to further extend
this discovery and determine whether WSX1 has the same
function in Lewis Lung Carcinoma (LLC). First, we confirmed
WSX1 expression via western blot and flow cytometry in LLC
cells engineered to express either WSX1 or control GFP (Figure 1a,
left and right panels, respectively). The ATP light and clonogenic
assays of the genetically engineered LLC cells confirmed our
findings in the previous two types of tumor cells: LLC-WSX1 cells
grew significantly slower than the cognate control LLC-GFP cells
and resulted in a 5-fold reduction in clonogenic ability when
compared to LLC-GFP (Figure 1b, left and right panels,
respectively).
To test whether the same result would occur in-vivo,w e
compared the tumor growth difference between GFP- or WSX1-
positive LLC tumor cells in C57Bl/6 mice. Contrary to the in-vitro
results and the results of the other two tumor models [12], WSX1
promoted tumor growth in LLC (Figure 1c, left). Similarly, WSX1
enhanced tumor growth in another independent tumor model,
melanoma cell line AGS (Figure 1c, right).
To determine how WSX1 promotes LLC tumor in-vivo, the
WSX1 expression was examined for the abnormal localization in
the cell, which may have accounted for tumor promotion. The
confocal microscope results ruled out this possibility. Similar to
TC1-WSX1 cells; WSX1 was expressed on cell membrane in
LLC-WSX1 cells (Figure 1d).
WSX1 promotes tumor growth independently of IL27
WSX1 has an intracellular Box1 motif necessary to interact with
JAK1 although JAK2 has been shown to induce downstream
signaling [14,15,16]. Mutating conserved prolines in the Box1
motif or adding JAK inhibitors attenuates the downstream
signaling of WSX1, such as phosphorylation of STAT1/
STAT3/STAT5 [17]. Our previous data suggested that WSX1
inhibited tumor growth independently of IL27 signaling [12]. To
determine the dependency of WSX1 promotion of tumor growth
on IL27 signaling, we first assessed tumor growth differences
between LLC cells expressing full-length WSX1 (LLC-WSX1) and
WSX1-Mutant (LLC-MUT, lacking intracellular domain includ-
ing Box1 domain). If LLC-MUT-expressing tumors grew slower
than full-length WSX1 in wildtype mice, then it indicates that
IL27 promotes tumor growth; otherwise, IL27 does not explain
pro-tumorigenic abilities of WSX1. To confirm that IL27 induces
signaling only in LLC-WSX1 cells but cannot signal in control
LLC cells (GFP expressing cells) and LLC-MUT cells, STAT1
phosphorylation and STAT1 expression (trademarks of the IL27
signaling pathway) were analyzed [18]. As expected, IL27 is able
to signal in full-length WSX1 expressing cells, while in WSX1-
MUT cells (lacking intracellular domain of WSX1 and Box 1
domain), IL27 has lost the ability to induce phosphorylation and
expression of STAT1 (Figure 2a). To confirm that the assay was
successful, positive controls of WSX1-MUT ran side by side and in
the same gel with full-length WSX1 are included in Figure S1.
Figure 1. The paradoxical functions of WSX1 between in-vivo and in-vitro assays. (a) Detection of WSX1 expression via western blot (WB)
analysis (left) or flow cytometry (right) from LLC tumor cells transduced with retrovirus containing either control GFP or WSX1 gene. Cell extracts of
the established cell lines were analyzed using western blot techniques and probed with mouse WSX1 and actin antibodies. (b) Detection of the role
of WSX1 in tumor cell proliferation. GFP or WSX1 positive LLC cells were harvested on the indicated days and were analyzed for ATP release (left,
N=4, error bars are smaller than symbols). Comparative analysis of soft agar growth assay between LLC-GFP and LLC-WSX1 cells (right, data is
representative of two independent experiments, each experiment performed in triplicate). (c) Comparison of tumor growth between LLC-GFP and
LLC-WSX1 (left, N=4, representative of four independent experiments) or AGS-GFP and AGS-fWSX1 (right, N=5). (d) Detection of WSX1 localization
in the cell. Images of TC1-WSX1 (left) or LLC-WSX1 (right) cells expressing WSX1 gene were captured using a confocal microscope. Points, mean; bars,
SE. *, P,0.05 comparing GFP- to WSX1-positive tumors.
doi:10.1371/journal.pone.0019072.g001
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WSX1 or GFP cohorts, excluding the role of IL27 as a tumor
promoter (Figure 2b), suggesting that IL27 signaling in tumors
may inhibit tumor growth rather than promote tumor growth.
This result is in accordance with the result from others, in which
IL27 inhibits tumor growth through tumor inhibition of COX2
and PGE2 [19]. But, if IL27 signals in tumor cells and inhibits
tumor growth, then why do tumor cells that overexpress WSX1
grow faster than GFP control? One possibility is that tumors
overexpressing WSX1 compete with immune cells for IL27 and
reduce the bioavailability of IL27 to signal into immune cells since
IL27 generates anti-tumor activities via signaling through host
immune cells [20,21,22,23]. To exclude this possibility, we
compared tumor growth rates between GFP and WSX1-positive
LLC tumors in TCCR
2/2 mice. An increase in tumor growth
rates in WSX1-positive tumors compared to the cognate controls
in TCCR
2/2 mice (IL27 cannot signal in this host) suggests that
WSX1 expression in tumors does not act as a decoy receptor for
IL27 but rather promotes tumor growth via an alternate
mechanism. Indeed, similar to wildtype mice, WSX1-expression
in tumors promotes tumor growth in TCCR
2/2 mice (Figure 2c).
Moreover, IL27 signaling in WSX1 positive tumor cells (LLC-
WSX1) reduces rather than promotes tumor growth (Figure 2d),
consistent with other publications [13]. In summary, WSX1’s
ability to promote tumor growth is not mediated via IL27, but via
an alternate mechanism.
WSX1-mediated tumor growth promotion is not
dependent on NKG2D pathway
The NKG2D receptor plays an important role in the anti-tumor
immune response. Our previous study demonstrates that induction
of NKG2D ligands in the WSX1-engineered TC1 and AT84
tumor cells are associated with tumor growth inhibition [12].
However, disruption of the NKG2D pathway leads to the immune
escape of tumor cells. It is possible that WSX1 expression in LLC
failed to induce NKG2D ligands. As expected, WSX1 does not
induce NKG2D ligand upregulation in LLC tumor cells where
WSX1 promotes tumor growth (Figure 3a). The lack of NKG2D
ligands in WSX1-engineered LLC cells could be due to lack of the
induction or could be due to a known mechanism, such as
NKG2D ligand shedding by Erp5 [24,25]. If the shedding
mechanism plays a role, then we should observe a suppressed
NKG2D expression in immune cells in LLC-WSX1 tumors as
compared to the control LLC-GFP tumors, because the shedding
of soluble NKG2D ligands downregulates the NKG2D receptor in
immune cells [26]. Therefore, we investigated whether WSX1-
positive tumors affected NKG2D expression in NK
+ or CD8
+ cells
in-vivo. Our results showed that there is no significant reduction of
NKG2D receptors in either NK
+, or CD8
+ cells by WSX1
expression in tumor cells (Figure 3b). Moreover, the percentage of
immunosuppressive NKG2D
+CD4
+ T cells is similar between
GFP- and WSX1-positive tumors. Studies comparing the total
cellular (cells were permeabilized) or membrane expression of
NKG2D in the splenocytes of mice bearing LLC-GFP or LLC-
WSX1 revealed that extracellular and total cellular NKG2D
expression was increased rather than decreased by WSX1
(Figure 3c) suggesting that internalization of NKG2D is not the
mechanism that explains the pro-tumor properties of WSX1 in
LLC model. In summary, WSX1-expression in a lung tumor
model promotes tumor growth and is associated with a lack of
upregulation of NKG2D ligands. The lack of NKG2D ligand
upregulation explains why WSX1 does not have the anti-tumor
effects but does not explain why WSX1 promotes tumor growth in
this tumor model.
Figure 2. IL27-independent and WSX1-dependent tumor growth promotion. (a) Comparison of IL27 signaling function between WSX1-
and DN-WSX1 cells. Equal amounts of cell extracts of LLC cells expressing GFP, WSX1, or DN-WSX1 were treated with IL27 for 10 minutes (109),
overnight (24 hr), or left untreated (-), and then analyzed using WB techniques and probed with pSTAT1 and STAT1 antibodies. (b) Comparison of
tumor growth between LLC-GFP, LLC-WSX1, and LLC-MUT in wildtype C57Bl/6 mice (N=5). Representative of two independent experiments.
(c) Comparison of tumor growth between LLC-GFP and LLC-WSX1 in TCCR
2/2 mice (N=4). (d) Comparison of tumor growth between LLC-WSX1 and
LLC-MUT in TCCR
2/2 mice (N=4). Points, mean; bars, SE. *, P,0.05 between LLC-WSX1 and LLC-GFP. #,P ,0.05 between LLC-MUT and LLC-GFP.
doi:10.1371/journal.pone.0019072.g002
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WSX1 inhibits tumorigenicity and cell proliferation in-vitro,
while it promotes LLC tumor growth in-vivo (Figure 1). The ability
of WSX1 to promote LLC tumor growth was associated with a
lack of NKG2D ligand induction (Figure 3a) while WSX1’s ability
to attenuate TC1 tumor growth was associated with induction of
NKG2D ligands. The lack of NKG2D ligand induction in LLC-
WSX1 explains why LLC-WSX1 tumor growth was not inhibited,
but does not explain why these tumors grow faster than GFP
control. Such a result prompted us to hypothesize that WSX1
expression in the absence of NKG2D ligand upregulation
promotes immunosuppression and tumor growth while the
presence of NKG2D signaling overshadows the immunosuppres-
sion pathway, resulting in attenuated tumor growth. In other
words, such tumor growth differences between LLC-GFP and
LLC-WSX1 may be diminished in immunocompromised mice, in
which WSX1 is unable to suppress immune cell surveillance and
tumor growth is the same with or without WSX1 expression. To
test this hypothesis, we compared tumor growth rates between a
control and WSX1-expressing tumors in immunocompromised
nude mice. As seen in Figure 4a, T cell absence completely
abolished the ability of WSX1 to promote tumor growth. Similar
results were obtained in SCID mice too (data not shown). To
further support this finding, we investigated the phenotype of
immune cell infiltration in the tumor microenvironment of
immunocompetent mice. The total number of CD3
+ and CD4
+
T cells present in the tumor microenvironment was greatly
reduced in WSX1-positive tumors (Figure 4b). This observation is
not attributed to lack of T cell infiltration in the tumor
microenvironment, as adoptive transfer of CFSE-labeled CD3
+
T cells had similar tumor-infiltrating ability 16 hours post-transfer
(data not shown).
WSX1 induces immunosuppression in a cell contact-
dependent manner
To further characterize how WSX1 reduces the number of
immune cells, tumor cells expressing WSX1 or GFP were directly
co-incubated with splenocytes activated with CD3/CD28 anti-
bodies. Similar to the in-vivo results, the frequency of CD3
+, CD4
+,
CD8
+, and NK
+ cells was reduced by 40–60% in LLC-WSX1
tumors compared to LLC-GFP in culture systems (Figure 5a).
Figure 3. NKG2D-independent and WSX1-dependent tumor growth. (a) Comparison of NKG2D ligand expression in LLC cells transduced
with either GFP (shaded gray) or WSX1 (not shaded) stained with NKG2D-Fc followed by anti-human IgG-PE. (b) Comparison of NKG2D expression in
NK
+, CD8
+, and CD4
+ cells in the splenocytes of mice bearing LLC-GFP or LLC-WSX1 tumors, or mice without tumors. Splenocytes from tumor bearing
mice were pooled (5 mice/group), processed, and stained with the following antibodies: NK1.1-FITC, CD8-FITC, CD4-APC, and NKG2D-PE.
(c) Comparison of membrane-only or total cellular expression of NKG2D in the splenocytes of mice bearing LLC-GFP (dotted line) or LLC-WSX1 tumors
(solid line) or mice without tumors (shaded in gray). Processed splenocytes were either permeabilized (bottom panel, ii) or left untreated (top panel, i)
and stained with NKG2D-PE antibody.
doi:10.1371/journal.pone.0019072.g003
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IFNc. To determine if WSX1 expression in tumor cells affects
their ability to secrete IFNc, tumors and splenocytes were co-
incubated and the percentage of CD4
+ and CD8
+ cells expressing
IFNc was determined. The percentage of IFNc
+CD4
+ and
IFNc
+CD8
+ cells was also largely decreased in the presence of
LLC-WSX1 (Figure 5b) compared to the presence of LLC-GFP.
Furthermore, upon co-culturing with LLC-WSX1, NK cells
produced lower levels of IFN-c as compared to the co-culture
with LLC-GFP (Figure 5c, left). Similar results were also seen in
co-cultures of tumor and NK cells in the absence of IL2 (Figure 5c,
right). Thus, the presence of WSX1 in tumor cells directly reduced
the production of IFN-c by NK cells. Likewise, similar results were
seen in AGS tumor model (Figure 5d).
Although WSX1 affects T and NK cell number and cytokine
production, we wanted to assess whether WSX1 initiates
immunosuppression in a contact-dependent manner or via release
of secretable factors. To address this question, LLC-tumor cells
where co-incubated with splenocytes directly or separated via a
transwell barrier, and T cell number and cytokine production were
determined. The use of the transwell barrier reversed the ability of
WSX1 to reduce T cell number and IFNc production in T cells
(Figure 6a, 6b), suggesting that WSX1-positive tumors initiate
immunosuppression via a direct tumor/immune cell contact-
dependent manner.
WSX1-positive tumors trigger T cell death
So far, our findings illustrate that WSX1 expression in tumors
reduces the number of T cells and IFNc production by effector
immune cells. Next, we aimed to assess how WSX1 reduces T cells
population. To address this question, both cell proliferation and
cell death were examined in the presence of WSX1-positive or –
negative tumor cells. After 72 hours, CD4
+ and CD8
+ cells were
analyzed for expression of apoptotic markers and cell proliferation
via Flow cytometry. WSX1 expression in LLC tumor cells induced
elevation of activated caspases 8 and 9 and an increase in
percentage of late apoptotic T cells (positive staining for Annexin
V and PI) (Figure 7a). Interestingly, a large increase of both
activated caspase 8 and caspase 9 (16% and 11.2% increase,
respectively) was detected in CD8 T cells when co-incubated with
LLC-WSX1 tumor cells as compared to LLC-GFP control cells;
meanwhile, relatively small increases of the activated caspase 8
and caspase 9 (4.2% and 6.7% increase, respectively) were found
in CD4
+ T cells. These results suggest that WSX1 expression in
tumor cells induces both external and internal cell death signals in
T cells, causing cell death. No cell proliferation difference was
detected (data not shown).
The observation that WSX1-positive tumors induce T cell
death was further confirmed via trypan blue exclusion assay, in
which splenocytes were co-cultured with LLC-GFP or LLC-
WSX1 and the viable splenocytes were reduced in the presence of
WSX1-positive tumor cells as compared to the cognate control
cells (Figure 7b).
The results mentioned above do not distinguish whether
WSX1-expressing tumors affect T cell number directly or
indirectly (via affecting another cell type such as APCs). Thus,
purified CFSE-labeled CD3
+ cells were directly co-incubated with
tumor cells expressing either GFP or WSX1 at different ratios.
After 48 hours, the ratio of CD3
+ cells to tumor cells was
significantly reduced by WSX1-positive tumor cells (Figure 7c).
Such reduction was also shown in an in-vivo model, as systemic
transfer of CFSE-labeled CD3
+ T cells was significantly reduced in
the tumor microenvironment of LLC-WSX1 when compared to
control GPF tumor-bearing mice 6 days post-transfer (Figure 7d).
Discussion
Mechanisms of tumor escape from immune-facilitated destruc-
tion include many evasive strategies. Tumor-associated T cell
tolerance and T cell death is induced by several immune
suppressive molecules secreted or expressed by tumor associated
macrophages, myeloid-derived suppressor cells, tolerogenic DC
cells, Treg cells, or tumor cells in the tumor microenvironment
[27,28,29]. This study reveals that WSX1 expression in tumors
negatively regulates immune response in the tumor microenvi-
ronment via inducing apoptosis of T cells, and the receptor might
be a new target in immune therapy to reverse tumor tolerance in
the tumor microenvironment.
The underlying mechanisms by which known immune suppres-
sive molecules regulate immune suppression have been previously
explored. In multiple tumors, upregulation of PD-L1 and
subsequent binding to its receptor expressed in activated T cells
induces apoptosis, anergy, and exhaustion of effector or memory T
cells [4,5,6]. Upregulation of IDO, a tryptophan-degrading
enzyme, induces tryptophan depletion in the local surroundings,
which severely downregulates different facets of immune responses,
such as effector T cell populations, DC cells, and NK cells [7,8]. In
addition, another well-documented phenomenon associated with T
cell death is upregulation of FASL in solid tumor cells, which
activates the receptor FAS and intracellular signaling cascade in T
cells, resulting in T cell death [30,31].
In this study we reveal that similar to the immunosuppressive
molecules such as PD-L1 and FASL, WSX1 is a novel modulator
of the cross-talk between tumor and immune cells, which results in
inhibition of IFNc production from NK and T cells and induction
of apoptosis of T effector cells (Figs. 4–7). Multiple lines of in-vivo
and in-vitro evidence shown in this study support this conclusion.
First, in-vitro co-incubation of WSX1-positive tumor cells reduces
the number of T cells and induces a significant increase in caspase
8 and caspase 9 activation as well as an increase in late apoptosis
markers mainly in CD8, and to a lesser extent, in CD4 T cells.
Second, the number of intravenously injected CFSE-positive T
cells is significantly reduced 6 days post-transfer in the tumor
microenvironment in LLC-WSX1 tumor cells when compared to
control cohorts. The decreased presence of CFSE-positive T cells
in the tumor microenvironment is not due to T cell infiltration in
tumors, as the number of CFSE-labeled T cells after 16 hours
post-injection were similar between GFP and WSX1- positive
tumors (data not shown). Third, and most importantly, WSX1
cannot promote tumor growth in immune-compromised nude
mice, which once again confirms the ability of WSX1 to induce
immune tolerance (Figure 4a). Moreover, aberrant T cell
activation plays a key role in multiple autoimmune and chronic
inflammatory diseases, showing the therapeutic potential of WSX1
in other disease models. Indeed, transgenic mice expressing high
levels of WSX1 in MLR/lpr background rendered the autoim-
Figure 4. WSX1-mediated immunosuppression in the tumor microenvironment. (a) Comparison of tumor growth between LLC-GFP and
LLC-WSX1 in nude mice (N=5–6). (b) Comparison of the number of T cells in the tumor microenvironment between LLC-GFP and LLC-WSX1 tumor-
bearing mice. Tumors from 5 mice were pooled, processed, and then stained with CD3-APC or CD4-PE. Circled area represents T cell population.
Points, mean; bars, SE. *, P,0.05.
doi:10.1371/journal.pone.0019072.g004
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disease [32]. Such evidence, combined with our study, suggests
that WSX1 plays a key role in downregulating the immune
response in multiple disease models.
A hallmark of an effective immune response is the ability of T
and NK cells to effectively secrete IFNc. Secretion of IFNc plays a
key role in macrophage activation, inflammation, T helper 1 (Th1)
cell responses, tumor surveillance, immunoediting and host
defense against intracellular pathogens [33]. WSX1-positive tumor
cells reduce not only the number of T cells but also the percentage
of T and NK cells secreting IFNc, similar to the effect of CTLA
and PD-1 ligands [4,34,35]. Such inhibition is also observed in
Figure 5. Induction of immunosuppression by WSX1 expression in LLC tumor cells. Comparison of the effect of LLC-GFP vs. LLC-WSX1 (a)
tumor cells on the number of immune cells in-vitro. Splenocytes were co-incubated with the tumor cells mentioned above in the presence of anti-
CD3 and anti-CD28 antibodies for 72 hours and stained with the following antibodies: CD45-FITC, CD8-PeCy7, and CD4-PeCy7 (b) IFNc expression in
CD4
+ and CD8
+, cells was compared in splenocytes co-cultured with either LLC-GFP vs. LLC-WSX1. Purified NK cells in the presence or absence of IL2
(c, left and right, respectively) were cultured in the presence or absence (control) of the indicated tumor target cell lines, and IFN-c release was
determined by specific ELISA after 24 hours. Detection of the effects of AGS-GFP vs. AGS-fWSX1 on immune cells. Splenocytes and AGS tumor cells
were mixed and analyzed as in (a, b).
doi:10.1371/journal.pone.0019072.g005
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and T cell communication are in line with discoveries in other
disease models. For example, others found that WSX1 absence
will induce hyperproliferation of T cells after infection with
Trypanosoma cruzi [36], suggesting that the presence of WSX1 is
needed to suppresses T cell hyperproliferation after the infection.
IL27 has distinct features in the immune response and various
disease models, and these features vary from pro- to anti-
inflammatory. Some of the discordant functions seen by IL27
are due to the model used to study IL27 by either using IL27
knockout models used (WSX1
2/2, EBI3
2/2) or overexpression of
IL27. For example, in ConA-mediated hepatitis model, the lack of
WSX1 worsens the hepatitis score, while a lack of EBI3
ameliorates the hepatitis score [37,38]. Similar differences were
also observed in an arthritis model: in a CIA model administration
of IL27 systemically improves the clinical score, while in a
proteoglycan-induced arthritis model the lack of WSX1 also
improves the clinical scores [39,40]. The dissociation that is seen
in the autoimmune disease models is also observed in cancer-
related biology. Previous studies have shown that IL-27 expressing
tumors decrease tumor volume by enhancing NK and CTL
activity and inhibiting COX-2 expression [19,20,21]. In contrast,
other studies in conjunction to this study have shown that WSX1-
expressing tumors can either promote or inhibit tumor growth
independently of IL27 [12,17]. Similarly, IL27 plays a role not
only in tumor growth but also in metastasis. In lung carcinoma,
IL27 down-regulates vimentin expression and reduces cellular
migration and invasion. IL27 also inhibits metastasis in the
B16F10 and neuroblastoma TBJ tumor models [19,41,42].
Meanwhile, EBI3 knockout mice are less prone to experimental
metastasis of B16F10 [43]. To reconcile the opposing properties of
IL27 and WSX1 phenotypes in immune-related diseases or
cancer, it is likely that, in addition to WSX1 serving as a receptor
for IL27, WSX1 has properties independently of IL27.
Indeed, the findings presented here suggest that WSX1 has a
function independent of IL27. Direct co-incubation of WSX1-
positive tumor cells and purified CD3
+ T or NK cells inhibits T
cell numbers or NK cell’s ability to produce IFNc whereas neither
T, neither NK, nor tumor cells express IL27. More importantly,
tumor cells expressing mutated WSX1 (Figure 2) or subcutane-
ously inoculated in TCCR
2/2 (Figure 2) grow faster than control
cohorts, supporting the notion that inhibition of IL27 signaling in
either the host or the tumor does not affect the pro-tumorigenic
abilities and induction of tumor tolerance by WSX1.
The fact that WSX1 suppresses the immune system perfectly
explains why this tumor growth was promoted when WSX1
expression was elevated by genetically engineered LLC cells.
However, it does not explain why the growth of TC1 and AT84
tumors reported previously [12] were inhibited rather than
promoted. The most likely explanation is due to differences in
tumor cell type and the differences in the intrinsic immune evading
mechanisms of each cell type. Another likely explanation is that
WSX1 induces both activating and inhibitory signals in cancer cells
and the sum of these signals determines the outcome of the immune
response and tumor growth. The opposite effect (anti-tumor effect)
is determined by the presence of a strong group of immune
surveillance signals in the TC1 and AT84 tumor cells following the
genetically engineering with WSX1. It is possible that many positive
immune stimulation signals were induced in TC1 and AT84 and
one group of these immune surveillance stimulation signals are
Figure 6. Cell contact-dependent and WSX1-mediated immunosuppression. Detection of the effect of LLC-GFP or LLC-WSX1 tumor cells on
CD4
+ T cells number (a) and IFNc expression (b). Splenocytes and tumor cells were either mixed and seeded either in the bottom of the transwell (NO
BARRIER) or separated and seeded in the top and bottom of the transwell, respectively (BARRIER). The splenocytes without tumor cells were used as
control (SPLEEN). Cells were analyzed similarly as in Figure 5a.
doi:10.1371/journal.pone.0019072.g006
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were detected in TC1 and AT84 but were not detected in LLC and
Ags tumor cells following the WSX1 genetic engineering. This
difference offers a clue but not the final mechanism. In other words,
NKG2D ligands alone may not represent the entire immune
stimulation signals but just acts as a marker to distinguish which role
WSX1 will play. Unfortunately, this paradox needs additional
comprehensive studies to be resolved.
In recent years, it has become increasingly evident that lack of
successful anti-cancer therapies is mainly due to the immunosup-
pressive environment created by cancer cells. This study not only
demonstrates a novel molecular mechanism for the suppression of
immune responses in cancer via inducing T cell death and inhibition
of pro-inflammatory cytokine production but also presents a
molecular link of the crosstalk between cancer and T cells via WSX1.
Materials and Methods
Cell culture and reagents
Mouse cancer cell lines AGS and LLC were kindly provided by
Dr. William E. Carson (The Ohio State University, Columbus,
Ohio) and Dr. Augusto C. Ochoa (Louisiana State University,
School of Medicine, New Orleans, LA), respectively. Other
reagents were purchased commercially, which include recombi-
nant mouse IL27, NKG2D/Fc, recombinant human IL2, and
anti-CD3 (R&D Systems, Minneapolis, MN, USA); anti-
pSTAT1-701, anti-STAT1, anti-hamster IgG-FITC, and anti-
hamster IgG-APC (Santa Cruz, Santa Cruz, CA, USA); anti-
NKG2D-Pe, anti-NK1.1-FITC, anti-CD4-APC, anti-CD4-FITC,
and anti-CD28 (Biolegend, San Diego, CA, USA); anti-CD8-
FITC (BD Biosciences, Chicago, IL, USA), and anti-IFNc-APC,
CD45-FITC, CD8-PeCy7, and CD4-PeCy7 (eBiosciences, San
Diego, CA, USA). Mouse anti-WSX1 was provided by Dr. Fred
de Sauvage (Genentech, San Francisco, CA, USA).
Flow Cytometry
Cells were stained with the indicated antibodies for 30 min at
4uC as indicated in each figure. The expression of the indicated
genes was analyzed on FACS Calibur (BD Biosciences, San Jose,
CA,USA)andFCSExpress3(DeNovoSoftware,LosAngeles,CA,
USA).Forintracellularstaining,BDBiosciencesintracellularkit was
used according to manufacturer’s instructions. Annexin V and
activated caspase 8 and 9 (Biovision, Mountain View, CA, USA)
staining were performed according to manufacturer’s instructions.
Cell proliferation, soft agar growth assay, and western
blot
These assays were performed per protocol as previously
described [12].
Statistical analysis
For in-vivo experiments, Univariate Repeated Measures AN-
OVA was used to analyze the difference among treatments using
SAS version 9.1.3. When appropriate, Tukey’s HSD test was
performed for interaction affects. For in-vitro results, student’s T
test analysis was conducted.
Cell harvesting, purification, and CFSE staining
Spleens were mashed through a 70 mm cell strainer (Fisher,
Pittsburgh, PA, USA) to obtain single cell suspensions. CD3
+ T
and NK cells were purified using negative selection according to
manufactures instructions (Stem Cell Separation, Vancuver, BC,
Canada). Splenocytes or CD3
+ T cells were labeled with 20 mM
CFSE for 15 minutes at 37uC (Invitrogen, Carlsbad, CA). Tumor-
infiltrating lymphocytes were obtained by removing tumors,
chopping them into pieces, and resuspending the mixture in
sterile PBS (without Ca
2+ and Mg
2+) in the presence of a digestion
enzyme mixture of collagenase IV, hyaluronidase V, and DNase II
(Fisher).
Confocal microscopy
TC1 and LLC cells expressing fWSX1 were seeded onto glass
slides and fixed. The slides were visualized and photographed
using Leica TCS SP2 confocal microscope with the help of Dr.
Xiaochu Wu (Louisiana State University).
Adoptive T cell transfer
5*10
6 CFSE-labeled CD3
+ T cells were suspended in 100 mLo f
PBS and injected i.v. into mice bearing LLC-GFP or LLC-WSX1
tumors at 300 mm
3. The mice were sacrificed 16 hours and 6 days
post adoptive transfer, tumors were harvested and processed via
enzyme digestion, and CFSE-positive cells in the tumor microen-
vironment were documented via flow cytometry.
Establishing stable WSX1 and IL27-signaling defective
WSX1 (WSX1-MUT) expressing cell lines
The murine WSX1 full length gene (gene bank # BC032878)
was purchased from Open Biosystems (Huntsville, AL, USA) and
subcloned into pBMN-GFP (Phoenix
TM Retrovirus Expression
System) for generating bicistronic gene expression system, the
WSX1-IRES-GFP retroviral construct. The murine WSX1 full
length gene was first subcloned into pDsRed-Express vector
(Clontech Laboratories, Mountain View, CA, USA) to make the
WSX1-DsRed fusion gene (referred to as WSX1 throughout the
manuscript). The fusion gene was subsequently cloned into pBMN-
GFP, resulting in the WSX1-DSRed-IRES-GFP retroviral construct.
The Lac Z gene in pBMN-Z plasmid (Phoenix
TM Retrovirus
Expression System), was replaced with the WSX1-DsRed fusion
gene (rWSX1) from above for generating the WSX1-DSRed
retroviral construct. WSX1 without cytoplasm domain was PCR
amplified from WSX1 gene and subcloned to pDsRed-Express to
make the WSX1-MUT-DsRed fusion gene (WSX1-MUT). The
fusion gene (WSX1-MUT-DsRed) lacking the cytoplasm domain of
WSX1 was subsequently cloned to pBMN-GFP for generating the
WSX1-MUT-DSRed-IRES-GFP retroviral construct. The retrovirus
was generated by transfecting WSX1-IRES-GFP, WSX1-MUT-
Figure 7. Effect of WSX1 on T cell numbers. (a) Comparison of apoptosis markers in CD4
+ and CD8
+ T cells when co-incubated with LLC-GFP or
LLC-WSX1 tumor cells. Splenocytes and tumor cells are co-incubated as in Figure 5A, and then cells gated for CD4
+ (left) or CD8
+ (right) markers were
analyzed for Annexin V and propidium iodine (PI) expression, Caspase 8, and Caspase 9. Representative of two independent experiments.
(b) Comparison the differences in splenocytes cell numbers in the presence of either LLC-GFP or LLC-WSX1 tumor cells. Cells were seeded as in
Figure 5A, and viable splenocytes were counted via tryptophan blue exclusion. (c) Comparison of purified and CFSE-labeled CD3
+ T cell numbers in
the presence of either LLC-GFP or LLC-WSX1 tumor cells. Data is presented as ratio of gated CFSE-positive lymphocytes (gating based on size in FSC
vs. SSC) to tumor cells. (d) Detection of CFSE-positive lymphocytes within the tumor microenvironment 6 days post-transfer of tail-vein injection of
CFSE- labeled CD3
+T into LLC-GFP or LLC-WSX1 tumor-bearing mice. N=4. Representative of two independent experiments. Points, mean; bars, SE.
*, P,0.05.
doi:10.1371/journal.pone.0019072.g007
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Phoenix Eco packaging cells. LLC and AGS cells were transduced
with retrovirus containing the gene of interest and the positive
fluorescent cells were sorted using a BD FACS Aria III cell sorter.
In-vitro co-incubation assays
Both T cells and splenocytes were used for co-incubation with
tumor cells. For T cells, 1*10
6 CFSE-labeled CD3
+ T cell were co-
incubated with 1*10
5 or 2.5*10
4 tumor cells in a 12-well plate for
48 hours in total of 2 mL media, and cells were analyzed via FCS
Express Software. For splenocyte co-incubation study, 2*10
6
splenocytes and 2*10
5 tumor cells were mixed and seeded.
Splenocytes or CD3
+ T cells were activated with anti-CD3 and
anti-CD28 antibodies at concentrations of 2.0 and 0.5 mg/ml,
respectively. NK cells were isolated from C57BL/6 splenocytes
according to the manufacturer’s instructions (Stem Sep) and
expanded for 3 days with 4000 U/ml human IL-2. A total of
3*10
4 NK cells was cultured 1*10
4 tumor target cells in the
presence of 1000 U/ml human IL-2 for 24 h. Concentrations of
mouse IFN-c in the supernatants were determined by ELISA
(eBiosciences).
Animal procedures
Six- to eight-week-old C57Bl/6 and C57Bl/6-WSX1
2/2
(TCCR
2/2) mice were used for this study with the approval
from IACUC at Louisiana State University, LA (08-098) and The
University of Texas M.D. Anderson Cancer Center, TX (03-10-
01031). The tumor models were generated by subcutaneously
inoculating LLC and AGS tumor cells (2610
5 in a 30-mL volume
per mouse) into mice. Tumor measurement and calculation were
the same as described previously (Puisieux et al., 1998). TCCR KO
mice were provided by Dr. Fred de Sauvage (Genentech), while
other mice were purchased from commercial sources.
Supporting Information
Figure S1 Full length blots of cropped gels shown in Figure 2a
ran side by side with a positive control.
(TIF)
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